Trial · NCT07382960
Pramipexole and the Risk of Serious Adverse Events
NCT07382960, Active not recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pramipexole and the Risk of Serious Adverse Events. Trials, record NCT07382960. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07382960
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pramipexole and the Risk of Serious Adverse Events
- NCT number
- NCT07382960
- Status
- Active not recruiting
- Enrollment
- 1,100 participants, actual
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Conditions
- Older Adults (65 Years and Older), Chronic Kidney Disease (CKD)
- Interventions
- Pramipexole
- First posted
- 2026-02-03
- Last updated
- 2026-09-14
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with a composite outcome of all-cause hospitalization or all-cause emergency visits, or all-cause mortality | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | All-cause hospitalization, all-cause emergency visits, and all-cause mortality will be combined into a composite measure. Only the first hospitalization or first emergency department visit occurring within 30 days after the cohort entry date will be considered. |
| Secondary | Number of participants with all-cause hospitalization | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | One of the components of the primary composite outcome, all-cause hospitalization, individually presented as a secondary outcome. Only the first hospitalization occurring within 30 days after the cohort entry date will be considered. |
| Secondary | Number of participants with all-cause emergency department visits | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | One of the components of the primary composite outcome, all-cause emergency department visit, individually presented as a secondary outcome. Only the first emergency department visit occurring within 30 days after the cohort entry date will be considered. |
| Secondary | Number of participants with all-cause mortality | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | One of the components of the primary composite outcome, all-cause mortality, individually presented as a secondary outcome. |
| Other | 30-day composite outcome of a hospital encounter with atrial fibrillation/flutter or other arrhythmia | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | 30-day hospital encounter (hospital admission or emergency visit) composite of atrial fibrillation/flutter or other arrhythmia (including pacemaker insertion, palpitations, tachycardia unspecified, atrioventricular block, supraventricular tachycardia, other conduction disorders, implantable cardiac defibrillator) |
| Other | 30-day composite outcome of a hospital encounter with heart failure or myocardial infarction, or ischemic stroke | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | 30- day hospital encounter (hospital admission or emergency visit) composite of Heart failure or myocardial infarction (most responsible diagnosis), or ischemic stroke (most responsible diagnosis) |
| Other | 30- day composite outcome of a hospital encounter with delirium, encephalopathy, or hospital admission with receipt of an urgent computed tomography scan of the head | Exposed cohort to pramipexole (high dose (0.25 or 0.375 mg/d)) versus (low dose (0.125 mg/d)) will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date. | 30-day composite outcome of a hospital encounter (hospital admission or emergency visit) with delirium or encephalopathy (disorientation, transient alteration of awareness, other and unspecified symptoms and signs involving cognitive function) or hospital admission with receipt of an urgent computed tomography scan of the head. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07382960
GET https://conductscience.org/api/trials/v1/NCT07382960/registered